Monocyte to HDL cholesterol ratio predicts obesity-associated cardiac dysfunction

Abstract

As the prevalence of obesity increases dramatically, obesity-associated cardiac dysfunction constitutes a considerable challenge to human health. This study aimed to identify more useful lipid/inflammatory markers to predict the risk of obesity-associated cardiac dysfunction. By retrospectively analyzing the clinical characteristics of 5648 cardiac disease patients, we found that both the plasma level of high-density lipoprotein cholesterol (HDL-C) and the blood monocyte count were significantly associated with impairment of the left ventricular ejection fraction (LVEF). Univariate and multivariate regression analyses revealed that the monocyte to HDL-C ratio (MHR) was a more powerful predictor of the risk of LVEF decline than either HDL-C or monocyte alone. Mediation analysis further revealed a mediating effect of a high MHR on the decline in obesity-associated cardiac systolic function. Collectively, our results demonstrate a superior role of MHR in predicting the risk of an obesity-associated decline in cardiac systolic function among routine metabolic/inflammatory markers.

Keywords

cardiac dysfunction / obesity / monocyte to HDL-C ratio / left ventricular ejection fraction

Funding

This work was supported by grants from the National Natural Science Foundation of China (Grant Nos. 82430018 to Q.C., 82270361 and 82570402 to H.Z.), the Nanjing Medical University Undergraduate Innovation and Entrepreneurship Training Program Fund (Grant No. 202410312138Y to C.Z.), and the Basic Sciences of Jiangsu Higher Education Institutions (Grant No. 22KJA310002 to H.Z.)

Acknowledgments

None.

Additional information

The online version contains supplementary materials available at http://www.jbr-pub.org.cn/article/doi/10.7555/JBR.38.20240432?pageType=en.

References

[1] Larenas-Linnemann D, Rodríguez-Pérez N, Arias-Cruz A, et al. Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions[J]. World Allergy Organ J, 2020, 13(11): 100476. doi: 10.1016/j.waojou.2020.100476

[2] The Writing Committee of the Report on Cardiovascular Health and Diseases in China, Hu S. Report on cardiovascular health and diseases in China 2021: An updated summary[J]. J Geriatr Cardiol, 2023, 20(6): 399-430. doi: 10.26599/1671-5411.2023.06.001

[3] Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China: The China Hypertension Survey, 2012-2015[J]. Eur J Heart Fail, 2019, 21(11): 1329-1337. doi: 10.1002/ejhf.1629

[4] Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population[J]. Eur Heart J, 2001, 22(3): 228-236. doi: 10.1053/euhj.2000.2289

[5] Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure[J]. JAMA, 1996, 275(20): 1557-1562. doi: 10.1001/jama.1996.03530440037034

[6] The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: A pooled analysis of 97 prospective cohorts with 1.8 million participants[J]. Lancet, 2014, 383(9921): 970-983. doi: 10.1016/S0140-6736(13)61836-X

[7] van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy[J]. Cardiovasc Res, 2011, 92(1): 10-18. doi: 10.1093/cvr/cvr212

[8] Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis[J]. Gastroenterology, 2011, 141(4): 1393-1403.e5.

[9] Lüscher TF. Preventive cardiology in adolescents and the elderly: LDL, HDL, and inflammation[J]. Eur Heart J, 2019, 40(43): 3503-3506. doi: 10.1093/eurheartj/ehz824

[10] Ghattas A, Griffiths HR, Devitt A, et al. Monocytes in coronary artery disease and atherosclerosis: Where are we now?[J]. J Am Coll Cardiol, 2013, 62(17): 1541-1551. doi: 10.1016/j.jacc.2013.07.043

[11] Ganjali S, Gotto AM Jr, Ruscica M, et al. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases[J]. J Cell Physiol, 2018, 233(12): 9237-9246. doi: 10.1002/jcp.27028

[12] Liu H, Jiang Z, Yang Z, et al. Monocyte to high-density lipoprotein ratio predict long-term clinical outcomes in patients with coronary heart disease: A meta-analysis of 9 studies[J]. Medicine (Baltimore), 2022, 101(33): e30109. doi: 10.1097/MD.0000000000030109

[13] Pei G, Liu R, Wang L, et al. Monocyte to high-density lipoprotein ratio is associated with mortality in patients with coronary artery diseases[J]. BMC Cardiovasc Disord, 2023, 23(1): 451. doi: 10.1186/s12872-023-03461-y

[14] Cetin MS, Ozcan Cetin EH, Kalender E, et al. Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome[J]. Heart Lung Circ, 2016, 25(11): 1077-1086. doi: 10.1016/j.hlc.2016.02.023

[15] Chen J, Li C, Liu Z, et al. The role of monocyte to high-density lipoprotein cholesterol ratio in prediction of carotid intima-media thickness in patients with type 2 diabetes[J]. Front Endocrinol (Lausanne), 2019, 10: 191. doi: 10.3389/fendo.2019.00191

[16] Shah AM, Cikes M, Prasad N, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction[J]. J Am Coll Cardiol, 2019, 74(23): 2858-2873. doi: 10.1016/j.jacc.2019.09.063

[17] Unzek S, Popovic ZB, Marwick TH. Effect of recommendations on interobserver consistency of diastolic function evaluation[J]. JACC Cardiovasc Imaging, 2011, 4(5): 460-467. doi: 10.1016/j.jcmg.2011.01.016

[18] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ) final report[J]. Circulation, 2002, 106(25): 3143-3421. doi: 10.1161/circ.106.25.3143

[19] Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-analysis[J]. JAMA, 2013, 309(1): 71-82. doi: 10.1001/jama.2012.113905

[20] Dietz WH. The response of the US Centers for Disease Control and Prevention to the obesity epidemic[J]. Annu Rev Public Health, 2015, 36: 575-596. doi: 10.1146/annurev-publhealth-031914-122415

[21] Carrero JJ, Andersson Franko M, Obergfell A, et al. hsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: A healthcare-based study[J]. J Am Heart Assoc, 2019, 8(11): e012638. doi: 10.1161/JAHA.119.012638

[22] Jiang M, Yang JM, Zou HYY, et al. Monocyte-to-high-density lipoprotein-cholesterol ratio (MHR) and the risk of all-cause and cardiovascular mortality: A nationwide cohort study in the United States[J]. Lipids Health Dis, 2022, 21(1): 30. doi: 10.1186/s12944-022-01638-6

[23] Ravindra K, Rattan P, Mor S, et al. Generalized additive models: Building evidence of air pollution, climate change and human health[J]. Environ Int, 2019, 132: 104987. doi: 10.1016/j.envint.2019.104987

[24] Igartua JJ, Hayes AF. Mediation, moderation, and conditional process analysis: Concepts, computations, and some common confusions[J]. Span J Psychol, 2021, 24: e49. doi: 10.1017/SJP.2021.46

[25] Panico C, Felicetta A, Kunderfranco P, et al. Single-cell RNA sequencing reveals metabolic stress-dependent activation of cardiac macrophages in a model of dyslipidemia-induced diastolic dysfunction[J]. Circulation, 2024, 150(19): 1517-1532. doi: 10.1161/CIRCULATIONAHA.122.062984

[26] Zhao S, Zhong J, Sun C, et al. Effects of aerobic exercise on TC, HDL-C, LDL-C and TG in patients with hyperlipidemia: A protocol of systematic review and meta-analysis[J]. Medicine (Baltimore), 2021, 100(10): e25103. doi: 10.1097/MD.0000000000025103

[27] Schnabel RB, Yin X, Larson MG, et al. Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community[J]. Arterioscler Thromb Vasc Biol, 2013, 33(7): 1728-1733. doi: 10.1161/ATVBAHA.112.301174

[28] Sardu C, Paolisso G, Marfella R. Inflammatory related cardiovascular diseases: From molecular mechanisms to therapeutic targets[J]. Curr Pharm Des, 2020, 26(22): 2565-2573. doi: 10.2174/1381612826666200213123029

[29] Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: A scientific statement from the American Heart Association[J]. Circulation, 2021, 143(21): e984-e1010. doi: 10.1161/CIR.0000000000000973

[30] Khan SS, Ning H, Wilkins JT, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity[J]. JAMA Cardiol, 2018, 3(4): 280-287. doi: 10.1001/jamacardio.2018.0022

[31] Iliodromiti S, Celis-Morales CA, Lyall DM, et al. The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: A cohort study of 296 535 adults of white European descent[J]. Eur Heart J, 2018, 39(17): 1514-1520. doi: 10.1093/eurheartj/ehy057

[32] Niedziela J, Hudzik B, Niedziela N, et al. The obesity paradox in acute coronary syndrome: A meta-analysis[J]. Eur J Epidemiol, 2014, 29(11): 801-812. doi: 10.1007/s10654-014-9961-9

[33] Rohatgi A, Westerterp M, von Eckardstein A, et al. HDL in the 21st century: A multifunctional roadmap for future HDL research[J]. Circulation, 2021, 143(23): 2293-2309. doi: 10.1161/CIRCULATIONAHA.120.044221

[34] Morris G, Gevezova M, Sarafian V, et al. Redox regulation of the immune response[J]. Cell Mol Immunol, 2022, 19(10): 1079-1101. doi: 10.1038/s41423-022-00902-0

[35] Stadler JT, Marsche G. Obesity-related changes in high-density lipoprotein metabolism and function[J]. Int J Mol Sci, 2020, 21(23): 8985. doi: 10.3390/ijms21238985

[36] Schiattarella GG, Rodolico D, Hill JA. Metabolic inflammation in heart failure with preserved ejection fraction[J]. Cardiovasc Res, 2021, 117(2): 423-434. doi: 10.1093/cvr/cvaa217

[37] Kaplan JL, Marshall MA, McSkimming CC, et al. Adipocyte progenitor cells initiate monocyte chemoattractant protein-1-mediated macrophage accumulation in visceral adipose tissue[J]. Mol Metab, 2015, 4(11): 779-794. doi: 10.1016/j.molmet.2015.07.010

[38] Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease[J]. Nat Rev Cardiol, 2016, 13(1): 48-60. doi: 10.1038/nrcardio.2015.124

[39] Adali MK, Buber I, Kilic O, et al. Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients[J]. Acta Cardiol, 2022, 77(7): 632-638. doi: 10.1080/00015385.2021.1973770

[40] Lyon RC, Zanella F, Omens JH, et al. Mechanotransduction in cardiac hypertrophy and failure[J]. Circ Res, 2015, 116(8): 1462-1476. doi: 10.1161/CIRCRESAHA.116.304937

[41] Arrigo M, Jessup M, Mullens W, et al. Acute heart failure[J]. Nat Rev Dis Primers, 2020, 6(1): 16. doi: 10.1038/s41572-020-0151-7

[42] Iorga A, Cunningham CM, Moazeni S, et al. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy[J]. Biol Sex Differ, 2017, 8(1): 33. doi: 10.1186/s13293-017-0152-8